A scalable 3D spatial multi-omics method for high-plex morpho-molecular imaging of millimeter-thick tissues.

Authors

null

Hei Ming Lai

Chinese University of Hong Kong, Hong Kong, Hong Kong

Hei Ming Lai , Shuk Ling Chan

Organizations

Chinese University of Hong Kong, Hong Kong, Hong Kong, The Chinese University of Hong Kong, Hong Kong, Hong Kong

Research Funding

The Chinese University of Hong Kong

Background: Tissues are three-dimensional (3D). However, current histopathology only allows 2D and single-marker tissue views. Methods: We utilized tissue clearing, supramolecular histochemistry, light-sheet microscopy, and image processing algorithms to compile an end-to-end multi-modality pipeline for 3D digital pathology and oncology diagnostics development. Results: Our end-to-end solution allow parallelized, fully automated processing of formalin-fixed or paraffin-embedded tissues of 1cm3 size. With a tissue-to-image time of 6 days, the whole intact tissue block can be non-destructively imaged with our newly developed 3D HnE (Hematoxylin-analogue & Eosin stain) and 4-plex immunohistochemistry (IHC). Deep and homogeneous penetration of staining was achieved such that all stained markers can be quantified as ground truth. The stained and cleared tissue can be recycled for subsequent FFPE 2D histology over multiple cycles for higher-plex imaging, and is also applicable to simultaneous survey of mRNA with multiplexed fluorescent in situ hybridization (FISH), post-translational modifications such as histone modifications via IHC, and glycosylation profiling with lectins. Image analysis readily allows high-dimensional clustering of cells based on their multi-modal biomolecular expression profiles, morphology, spatial locations, and neighborhoods. The method is applicable to a wide variety of human and murine tissues. Conclusions: Our 3D digital pathology platform enables maximal information extracted for precision diagnostics and advanced biomedical research.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2024 ASCO Breakthrough

Session Type

Poster Session

Session Title

Poster Session B

Track

Thoracic Cancers,Breast Cancer,Gynecologic Cancer,Head and Neck Cancer,Hematologic Malignancies,Genetics/Genomics/Multiomics,Healthtech Innovations,Models of Care and Care Delivery,Viral-Mediated Malignancies,Other Malignancies or Topics

Sub Track

MedTech Devices and Inventions

Citation

J Clin Oncol 42, 2024 (suppl 23; abstr 162)

DOI

10.1200/JCO.2024.42.23_suppl.162

Abstract #

162

Poster Bd #

F6

Abstract Disclosures

Similar Abstracts

Abstract

2023 ASCO Genitourinary Cancers Symposium

The CONFIDENT-P trial: Clinical implementation of artificial intelligence assistance in prostate cancer pathology.

First Author: Rachel Flach

First Author: David H Aggen

Abstract

2022 ASCO Annual Meeting

Assessing PD-L1 without a biopsy and through PD-L1 PET imaging with 18F-BMS-986229.

First Author: Michael A. Postow